naftidrofuryl

Naftidrofuryl is a small molecule peripheral vasodilator primarily used in the management of peripheral and cerebral vascular disorders, including intermittent claudication due to peripheral arterial disease. It acts as a selective antagonist (and inverse agonist) of serotonin 5‑HT2 receptors, particularly the 5‑HT2A receptor, leading to inhibition of serotonin-induced vasoconstriction and platelet aggregation. Additionally, it enhances cellular oxidative metabolism by stimulating the tricarboxylic acid cycle and increasing ATP production, which may protect cells against ischemic metabolic effects. The drug is administered orally and has been marketed since at least 1968 for these indications[1][4][5][7].

Brand names

PraxileneArtocoronAzunaftilDi-ActaneDusodrilEnelbinFrilixGevatranIridusIriduxLuctorNaftiNaftilongNaftodrilNafoxalSodipryl retardVascuprax

Other names

nafronylnafronyl oxalatenaftidrofuryl oxalatenaftidrofurilonaftidrofurylum